drugset / Trial / NCT02987114
A Study to Evaluate the Safety, Tolerability and Efficacy of Oral Administration of PTL101 (Cannabidiol) as an Adjunctive Treatment for Pediatric Intractable Epilepsy
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the safety, tolerability and efficacy of oral administration of PTL101 (cannabidiol) for the treatment for pediatric intractable epilepsy. Study will include a 4-week observation period ,12 weeks of treatment and 2 weeks of follow up.
Timeline
- Start
- 2017-02-13
- Primary completion
- 2018-06-28
- Completion
- 2018-06-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PTL 101 | Unknown | 25 mg/kg | Oral |
| Subject | PTL 101 | Unknown | 450 mg | Oral |